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Abstract
Alcohol use disorder (AUD) is a chronic debilitating disorder with limited treatment options and poorly defined
pathophysiology. There are substantial genetic and epigenetic components; however, the underlying mechanisms contributing
to AUD remain largely unknown. We conducted the largest DNA methylation epigenome-wide association study (EWAS)
analyses currently available for AUD (total N= 625) and employed a top hit replication (N= 4798) using a cross-tissue/cross-
phenotypic approach with the goal of identifying novel epigenetic targets relevant to AUD. Results show that a network of
differentially methylated regions in glucocorticoid signaling and inflammation-related genes were associated with alcohol use
behaviors. A top probe consistently associated across all cohorts was located in the long non-coding RNA growth arrest
specific five gene (GAS5) (p < 10−24). GAS5 has been implicated in regulating transcriptional activity of the glucocorticoid
receptor and has multiple functions related to apoptosis, immune function and various cancers. Endophenotypic analyses
using peripheral cortisol levels and neuroimaging paradigms showed that methylomic variation in GAS5 network-related
probes were associated with stress phenotypes. Postmortem brain analyses documented increased GAS5 expression in the
amygdala of individuals with AUD. Our data suggest that alcohol use is associated with differential methylation in the
glucocorticoid system that might influence stress and inflammatory reactivity and subsequently risk for AUD.
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Introduction
Multiple pathways to the development of alcohol use
disorder (AUD) exist and include a complex interplay of
environmental and genetic risk factors [1]. Genetic factors
have been suggested to play a significant role in the etiology
of AUD, as evidenced by twin, family, and adoption studies
with heritability estimates ranging between 40 and 60%
[2–4]; however, identifying the risk alleles has been difficult
due to the complex mode of inheritance, significant clinical
and genetic heterogeneity, and large number of genetic
variants involved, each only contributing a small fraction to
the overall risk.
The field of epigenetics is rapidly developing in AUD
and might help explain some of the environmental com-
ponents as they interact with the genetic architecture [5–8].
Several mechanisms contribute to epigenetic regulation,
broadly defined as changes in gene expression without
DNA sequence alterations, including histone modifications,
non-coding RNA, and DNA methylation changes [9]. It is
thought that various epigenetic mechanisms contribute to
the pathophysiology of addictions. Some are drug-specific,
while others are more generally involved in common
pathways that lead to maladaptive and addictive behaviors
[1, 10, 11].
While there has been some work on all of these epigenetic
mechanisms in AUD, in particular, using various animal
models [6, 12, 13], most studies were candidate gene driven
and only a few studies used human tissue e.g. ref. [14].
Recent availability of DNA methylation array capture for
comprehensive genome-wide profiling, has made it possible
to conduct epigenome-wide association studies (EWASs).
Only a few EWAS for AUD exist, but they are limited by
small sample sizes, low array-capture, tissue types,
inconsistent analysis strategy, and data interpretation [15–25].
Consequently, no universal DNA methylation loci for AUD
have been identified; however, recent data suggest multiple
loci associated with mild-moderate alcohol consumption [26]
and interesting new targets for AUD [27].
To address these gaps in the literature, we conducted the
largest EWAS analyses currently available for AUD using a
cross-tissue/cross-phenotypic approach with the goal of
identifying novel epigenetic targets relevant to AUD.
Materials and methods
Subjects
We used epigenome-wide data from six independent
cohorts as follows (see also Fig. 1).
Discovery cohort (blood, N= 539)
The discovery cohort comprised 539 participants (336 AUD
and 203 controls) and was recruited at the National Institute
on Alcohol Abuse and Alcoholism (NIAAA) at the National
Institutes of Health (NIH), USA. All participants completed
the Structured Clinical Interview for Diagnostic and Sta-
tistical Manual of Mental Disorders (DSM)-IV-TR (SCID-
IV) [28] and an alcohol dependence (AD) diagnosis was
determined. A diagnosis of AD in the DSM-IV is equivalent
to moderate to severe AUD diagnosis according to the
DSM-5 with a concordance of 93% [29]. In this manuscript
we use AUD to be consistent with current nomenclature.
Subjects completed several self-report questionnaires and
clinical assessments. Peripheral blood was obtained for
subsequent biomarker and DNA methylation analyses. All
Fig. 1 Flowchart of analyses
and datasets used. Six
independent cohorts were
assessed. These included the
discovery sample, three
replication cohorts, and two
post-mortem brain cohorts.
AUD alcohol use disorder, FDR
false discovery rate, GS
Generation Scotland: Scottish
Family Health Study, GTP
Grady Trauma Project,
WCGNA weighted genome
coregulation network analysis,
BOLD blood oxygen level-
dependent, fMRI functional
magnetic resonance imaging,
MRI magnetic resonance
imaging, GAS5 growth arrest
specific 5, FKBP5 FK506-
binding protein 5.
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participants provided written informed consent in accor-
dance with the Declaration of Helsinki and the study was
approved by the Institutional Review Board of the NIAAA.
Detailed demographic information can be found in Sup-
plementary Table S1.
First replication cohort (blood, N= 86)
The first blood replication cohort included 86 participants
(43 AUD and 43 controls) recruited to the NIAAA intra-
mural program for a study on fear conditioning and
extinction in AUD. Participants were included if they met
the following criteria: between 21 and 65 years of age, able
to provide written informed consent and cleared for venous
access. In the AUD group, participants were also required to
have a diagnosis of AD as assessed by the SCID-IV, to
specify alcohol as their drug of choice, and to report alcohol
consumption within the last 30 days on the Timeline Follow
Back (TLFB) [30]. Participants were excluded if in their
history and physical examination they reported neurological
symptoms of the wrist or arm or reported chronic use of
psychotropic medications within 4 weeks, fluoxetine use
within 6 weeks, or incidental use of psychotropic medica-
tion within 5 half-lives of the beginning of the study.
Additional exclusion criteria included presence of ferro-
magnetic implants, pregnancy, breastfeeding, left-handed-
ness, claustrophobia, magnetic resonance imaging- (MRI-)
incompatible intrauterine device or DSM-IV diagnosis of
bipolar disorder, psychotic disorder, or current substance
dependence other than alcohol, nicotine, or caffeine. Parti-
cipants not seeking treatment for AUD were excluded if
they had a history of alcohol-related seizures or presented
with alcohol withdrawal symptom scores ≥ 8 on the Clinical
Institute Withdrawal Assessment Alcohol Revised (CIWA-
Ar) [31]. All participants provided peripheral blood for
various biomarker assessments and DNA methylation stu-
dies. All participants provided written informed consent in
accordance with the Declaration of Helsinki and the study
was approved by the Institutional Review Board of the
NIAAA. Detailed demographic information can be found in
Supplementary Table S2.
Second replication cohort (blood, N= 4301)
The second replication cohort was from the Generation
Scotland: Scottish Family Health Study (GS), a family-
based cohort described elsewhere [32, 33]. Briefly, this
cohort includes over 24,000 participants age 18–99 recrui-
ted between 2006 and 2011 for no specific disorder across
Scotland. Alcohol consumption was assessed at baseline
using a pre-clinical questionnaire and participants self-
identified as current, former, or never drinkers. Average
consumption was a self-report measure reflecting average
weekly use in units. A table containing the units of alcohol
contained in various drink types was available in order for
participants to accurately estimate intake. All components
of the GS received ethical approval from the National
Health Service Tayside Committee on Medical Research
Ethics (REC Reference Number: 05/S1401/89) and written
consent was obtained from all participants. DNA methyla-
tion data was obtained for 5190 GS individuals from per-
ipheral blood samples taken at baseline using the Infinium
MethylationEPIC BeadChip. After quality control, 4301
participants were included in the analyses.
Third replication cohort (blood, N= 391)
The third blood replication cohort included participants
from the Grady Trauma Project (GTP), and details of the
sample have been described previously [34–36]. In brief,
the GTP was a study on stressful life events and their pre-
dictors in a predominantly African American, urban popu-
lation of low socioeconomic status. The sample included
1561 individuals who were recruited from a primary care
clinic where they provided written informed consent, after
which they completed a verbal interview and a blood draw.
From this cohort, epigenetic information was available for
391 participants (females = 115, males = 276). The SCID-
IV was administered and information on lifetime AUD was
available for 328 of the 391 participants.
Postmortem brain cohorts (N= 58 and N= 46)
Information on DNA methylation of neural tissues was
available from two postmortem cohorts. First, postmortem
frontal cortex fluorescence activated cell sorted (FACS)
neuronal and glial tissues of 58 individuals with and without
major depressive disorder were available for analysis as
described previously [37]. Of these 58 individuals, 7 had
alcohol use problems (defined retrospectively based on
responses to clinical interviews). Second, DNA methylation
data on postmortem samples from a cohort of 46 participants
with and without alcohol use problems was available from the
Gene Expression Omnibus (GSE49393). This dataset inclu-
ded samples from individuals with DSM-IV defined AD (n=
9), alcohol abuse (n= 14), as well as an age-matched healthy
control group (n= 23). For our study, we combined data from
participants with AD and alcohol abuse to define a new
group, ‘AUD’ (n= 23). Sample collection and processing for
this cohort have been described in a previous publication [38].
Methylomic profiling
DNA methylation data from whole blood samples were
assessed using an Infinium MethylationEPIC BeadChip
microarray (Illumina Inc., San Diego, California) according
Epigenome-wide association study and multi-tissue replication of individuals with alcohol use disorder:. . .
to the manufacturer’s protocol for the discovery, first, and
second replication cohorts (NIAAA and GS). The third
replication sample (GTP) and neural tissues from both
postmortem cohorts were assessed with the Illumina 450K
chip as described previously [37, 38]. Pre-processing of the
GS data has been described in detail elsewhere [39].
Statistical analysis
Raw data from discovery and replication cohorts were
processed with the package ‘wateRmelon’ in R [40]. All
cross-reactive probes and probes failing quality assessment
were removed. Scale-based correction was applied to Illu-
mina type I versus type II probes. Methylated and unme-
thylated intensities were quantile-normalized in the red and
green channels separately using the Dasen method in
WateRmelon [40], followed by β-value (intensity ratios of
methylated to unmethylated probes) calculation. All ana-
lyses were carried out in R, version 3.5.1 (© 2018 The R
Foundation for Statistical Computing).
Linear regressions were used to examine the associations
of each CpG site with AUD in the discovery and first
replication cohort. DNA methylation beta values were
regressed on AUD status adjusting for age, sex, race, and
cell type composition of blood. Cell type composition was
derived from DNA methylation proxies using the House-
man algorithm [41]. Significant probes (p ≤ 0.05) in both the
discovery and first replication cohorts were identified and
further examined as follows.
All probes identified above were tested for associations
with AUD diagnosis in the second (GS) and third (GTP)
blood replication cohorts. Associations were tested in the
GTP cohort using linear regressions as described above. In
the GS cohort, linear regression models were fit in the
limma R packages with CpG site as an outcome variable
and log transformed units per week as an independent
variable. Age, sex, smoking status, pack years of smoking,
and the first 20 principal components from the M-values
corrected for age, sex, relatedness batch, and estimated cell
counts were fit as covariates in the linear model.
Postmortem brain analysis
Methylation levels of the target probes were regressed on
alcohol use status controlling for age, sex, and race (only in
the first postmortem set), either separately for neuronal and
glial tissue (first postmortem dataset) or adjusting for neural
cell type proportion (second postmortem dataset).
Weighted genome coregulation network analysis (WGCNA)
WGCNA was performed to detect clusters (modules) of
highly correlated genes using the top 96 probes exhibiting
consistent FDR significance with AUD diagnosis from the
discovery and replication cohorts. Module detection was
carried out using a soft thresholding power β of 9, which
was chosen by maximizing scale free topology model fitting
as a function of model connectivity based on the internal
data structure according to the recommendations of Horvath
[42]. All analyses were performed in R.
Mediation network analysis
A mediation analysis approach was performed on
WGCNA identified module loci such that each loci in the
top 30th percentile of module membership or ‘hubness’ is
assessed for association to the outcome metric (cortisol,
see results), both alone and in conjunction with every
other module locus to assess for mediation. Those con-
nections implicated as mediating by means of statistical
association below 5% with the outcome alone and no
association in an additive model are considered ‘con-
nected’. Connected genes are quantified and displayed
using the iGraph package in R.
Endophenotype analysis
Cortisol measurements and assessments
All blood samples were taken before 09:00 AM after
inpatient admission. Cortisol was measured using radio-
immunoassay (RIA) with an intra-assay and inter-assay
coefficient of variation of 3.5% and 14.3%, respectively.
BOLD fMRI of fear conditioning and extinction
(brain; N= 86)
Subject description provided under first replication cohort.
Fear conditioning task: The Fear Conditioning and
Extinction (FCE) experiment took place after individuals
with AUD had no withdrawal symptoms for at least two
consecutive days. Day 1 consisted of habituation, con-
ditioning, and two extinction blocks and Day 2 consisted
of extinction recall and renewal blocks. Galvanic skin
responses were obtained throughout the fMRI session
using Ag/AgCl electrodes (41 mm diameter). Two addi-
tional electrodes were placed on the wrist of the same
hand to deliver electrical stimulation (unconditioned sti-
mulus [US]; 0.5 s duration). The intensity level of elec-
trical stimulation was uncomfortable but tolerable as
determined by a personalized work-up on the first day.
Participants were presented with digital photographs of
two different rooms, each containing a lamp shade that
turned blue or yellow as the conditioned stimuli (CSs).
During conditioning, one of the colors was paired with a
0.5-s electrical stimulation (CS+) in 75% of the trials,
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while the other was never followed by a shock (CS−). For
further details please see [43].
fMRI data processing: Functional data were processed
using Statistical Parametric Mapping (SPM12b, Well-
come Department of Cognitive Neurology, London, UK)
based on MATLAB R2018b (MathWorks, Natick, MA,
USA). After removal of the first three individual func-
tional scans of the experimental conditioning phase to
avoid artefacts caused by magnetic saturation effects,
and prior to preprocessing, all images were visually
controlled for gross movement artefacts and anatomical
abnormalities; all images of the 86 subjects were included.
Scans were further corrected for signal‐to‐noise decrease
in single slices, using the denoising function of the
ArtRepair software (http://cibsr.stanford.edu/tools/huma
n-brain-project/artrepair-software.html, assessed 03 Jan,
2019). Afterwards, individual scans were spatially rea-
ligned to correct for head motion and normalized using
the warping parameters estimates of the individual
co-registered and segmented MPRGE image. Images were
normalized to an isovoxel size of 3.5 × 3.5 × 3.5 mm.
Subsequent smoothing was done using an isotropic
Gaussian kernel (8 mm FWHM).
The preprocessed fMRI data were then analyzed as a
block design for the conditioning phase in the context of the
general linear model approach using a two‐level procedure.
On the individual single subject level, the different condi-
tions (CS+ and CS−) were modeled (boxcar functions
convolved with the hemodynamic response function) as
explanatory variables together with the six movement
parameters to account for residual variance due to head
motion, and a single constant representing the mean over
scans. Both CS+ and CS− conditions in the fear con-
ditioning phase were modeled as separate regressors for
trials 2–20 since learning of CS+ (potential shock) versus
CS- (no shock) has not occurred yet during the first trial.
Subsequently, for each subject, linear contrast images were
computed for fear conditioning: ‘CS+ minus CS−‘, trials
2–20. For these individual contrast images, overall blood
oxygenation level-dependent (BOLD) responses were
assessed for the “effect of interest” provided by an analysis
of variance. Here, we specifically assessed small volume
adjusted BOLD responses of anatomical atlas-based a
priori Regions of Interest (ROI) as brain regions crucially
involved in emotion detection and regulation, i.e., left/right
amygdala, left/right hippocampus, left/right medial pre-
frontal cortex (mPFC) (i.e., aal-mask for Front_Med_Orb),
left/right insula, left/right rostral anterior cingulate cortex
(rACC, ROI as defined in a prior study [44], using the
WFU PickAtlas toolbox (http://fmri.wfubmc.edu/software/
PickAtlas). Parameter estimates of the ROI BOLD respon-
ses (identifying clusters with an initial voxel-level threshold
of P (uncorrected) < 0.005) were then extracted from the
cluster peak as SPM eigenvariates for further BOLD ana-
lyses as described below.
BOLD analysis: Associations between blood methylation
levels for our target probes and BOLD signal data (from the
first replication cohort) were examined. As the normality
assumption for residuals was not met for regressions of
methylation on BOLD signal, we used non-parametric
Kendall’s partial correlations. For this, we regressed out
inter-individual differences in cell type composition and
estimated the correlations of the residuals with BOLD sig-
nal, adjusting for age, sex, and race.
Structural MRI (brain; N= 193)
A subset of participants from the discovery cohort also
participated in a structural MRI study. Hippocampus
volumes were determined using the standard Freesurfer [45]
(version 5.3.0; surfer.nmr.mgh.harvard.edu) pipeline. The
individual T1-weighted images were automatically seg-
mented to measure gray matter volume of structures [46]
using the following steps: (1) The images were resampled to
1 mm3 voxels; transformed to Talairach space, the intensity
non-uniformity corrected [47]; and skull was stripped from
the images [48]; and finally auto-segmentation proceeded
with labels assigned based on probabilistic location of
structures. We conducted a reliability test by examining a
random number of the auto-segmented volumes with
recon_checker from FreeSurfer’s QATools. This included
checking for outliers, calculating signal-to-noise ratio, and
visually examining generated snapshots of brain volume
segmentation.
Targeted human postmortem brain mRNA analyses
(brain; N= 24)
Postmortem tissues were obtained from the New South
Wales Tissue Resource Centre (NSWBTRC) at the Uni-
versity of Sydney, Australia. Brain tissues from 11 males
with AUD and 13 controls were analyzed for amygdala
and prefrontal cortex (PFC). All AUD subjects had alco-
hol detected in blood and were also daily smokers at
the time of death. Total RNA was extracted from male
postmortem frozen brain tissue, using the RNeasy Lipid
Tissue mini Kit (Qiagen). One µg total RNA was reverse-
transcribed using SuperScript® III First-Strand Synthesis
SuperMix for qRT-PCR (Invitrogen). Real-time quanti-
tative polymerase chain reaction (PCR) was run in ViiA™
7 Real-Time PCR System using TaqMan Gene Expression
Assays (GAS5; Hs03464472_m1, Thermo Fisher). Data
and statistical analyses were performed using GraphPad
prism 8.0 (GraphPad Software Inc., San Diego, CA,
USA). An unpaired t-test was used to determine statistical
significance with p < 0.05.
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Results
Associations of DNA methylation in blood with AUD
status
We identified 69242 CpG probes that were significantly (p ≤
0.05) associated with AUD in the discovery cohort and
72941 probes in the first replication cohort, using a linear
regression model additively controlling for age, sex, and race
as covariates. Demographic and sample characteristics can be
found in Supplementary Tables S1 and S2. After false dis-
covery rate (FDR) correction for multiple testing (FDR
threshold p < 0.05), 5101 probes in the discovery and 203
probes in the first replication sample remained significant
(Figs. 1, 2a, b). Of these, 96 probes were consistently FDR
significant in both cohorts (notably all in the same direction),
representing an overlap significantly higher than that expec-
ted by chance (expected probability= 0.0006; 95% CI=
0.40–0.54) (Supplementary Table S3). To further refine this
set, we performed additional replication analyses using linear
models for quantitative alcohol consumption in Generation
Scotland: the Scottish Family Health Study (GS:SFHS) and
SCID lifetime AUD diagnosis in the Trauma Project (GTP)
(see Supplementary Tables S4, S5). Of the 96 originally
identified loci, a total of 70 exhibited significant (p < 0.05)
associations in at least one of the two cohorts. Notably, two
probes located within the long non-coding RNA growth
arrest specific 5 gene (GAS5) (GAS5a= cg06644515,
GAS5b= cg16290996) were among the CpGs most con-
sistently associated with AUD or alcohol use across all
cohorts investigated (Table 1).
As smoking is commonly comorbid with AUD and also
leads to DNA methylation changes, we carried out addi-
tional regressions to test if adjusting for smoking altered our
results for the 96 target probes. Methylation at each of the
96 probes was regressed on AUD status, controlling for
smoking (self-reported scores on the Fagerstrom’s test for
nicotine dependence) in addition to age, sex, race, and cell
type. All probes retained significant associations after
adjusting for smoking scores (Supplementary Table S6).
In order to address possible dose/life-time alcohol expo-
sure on methylation, we carried out additional exploratory
analyses in the discovery cohort. A metric of exposure was
calculated by multiplying the average number of drinks
per day by the number of years since their self-reported age
of drinking inception. Of the 96 CpG sites, 65 probes
exhibited significant associations with dose (Supplementary
Table S7), suggesting that the observed epigenetic associa-
tions in these cases may be a consequence of alcohol expo-
sure. Subset analyses for DNA methylation changes by
ethnicity and gender are shown in Supplementary Fig. 1 and
Supplementary Table S8.
Weighted genome coregulation network analysis
Given that methylomic variation is often correlated across
CpG sites, we conducted a Weighted Gene Coregulation
Network Analysis (WGCNA) adjusting for age, sex, and
ethnicity in the 96 probes significantly associated in both
the discovery and replication cohorts. We identified one
significant AUD associated module consisting of 50 probes
(Module association Rho= 0.76, P= 2.2 × 10−16, Supple-
mentary Table S9), containing glucocorticoid signaling
associated genes GAS5b, and FKBP5, inflammatory cyto-
kine driving genes LURAP1L and LURAP1L-AS1, and a
number of small nucleolar RNA (snoRNA) targets, among
others.
Gene ontology analysis
A gene ontology analysis identified a number of significant
biological pathways, including some potentially indicative
of dysregulated inflammatory processes (Supplementary
Table S10).
Fig. 2 Volcano plots of DNA methylation association with AUD.
Volcano plots depicting the effect sizes of DNA methylation asso-
ciation with AUD (x axis) as a function of the negative natural log of
the p value (y axis) for the discovery (a) and replication (b) cohorts.
Red dashed horizontal line depicts a nominal p value of 0.05. c Scatter
plot showing the relationship between module membership of probes
(x axis) versus associations with AUD status (y axis).
F. W. Lohoff et al.
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Association of top AUD associated loci and
coregulated modules with cortisol
Based on the WCGNA analyses which revealed top targets
relevant to the glucocorticoid system, we investigated DNA
methylation associations with morning cortisol (Fig. 3a).
Morning cortisol levels collected under the same protocol
were available across the discovery and first replication
cohorts and were subsequently combined and assessed for
associations with AUD coregulated module variation. The
first eigenvector of a principal component analysis was
generated for those 50 loci in the significant AUD asso-
ciated module identified by WGCNA in order to represent
the majority of this coregulated epigenetic variation. A
significant association with morning cortisol levels was
observed after adjusting for age, sex, and ethnicity (b=
−3.85 ± 1.63, F= 5.14, df= 4/309, p= 0.019) (Fig. 3). To
assess module gene functional importance to cortisol var-
iation, we employed a mediation network analysis approach
to identify loci with the highest number of cortisol asso-
ciated connections among coregulated genes. Of those 50
loci interrogated, GAS5b exhibited the most evidence for
connectedness in association to cortisol (N= 18) (Fig. 3b).
In light of its functional relationship with HPA axis reg-
ulation, we assessed the association between two of the
GAS5 probes and observed a significant association with
GAS5b (b= ‒17.87 ± 8.62, F= 4.70, df= 4/309, p=
0.039) but not GAS5a (data not shown) (Fig. 3b).
Association of DNA methylation with stress-related
AUD neuroimaging endophenotypes
We assessed BOLD activation during fear acquisition to
assess how DNA methylation associated with AUD was
associated with BOLD signal in different brain regions.
Significant associations (p ≤ 0.05) were observed after
adjusting for age, sex, and race in the left amygdala, and
both the left and right insula (Table 2 and Supplementary
Table S10). We next assessed associations with morning
cortisol and identified significant associations in both
the left and right vmPFC, and the right ACC (Table 2). As
the AUD associated coregulated DNA methylation module
above was associated with cortisol, we investigated the
association of the eigenvector with BOLD activation levels
Fig. 3 HPA axis metric associations with AUD associated DNA
methylation. a Scatterplot of morning cortisol (y axis) as a function of
AUD associated coregulated module eigenvector values (x axis).
b Network diagram from the network mediation analysis demonstrating
coregulated genes associated with morning cortisol in the discovery
dataset. c Scatterplot of morning cortisol (y axis) as a function of GAS5b
DNA methylation (x axis).
Table 2 Brain activity
associations with AUD
phenotypes.
Brain region BOLD AUD beta P value Cortisol Tau P value AUD eigenvector Tau P value
Amygdala (left) −0.09 0.028 −0.051 0.51 0.028 0.71
Amygdala (right) 0.035 0.49 −0.089 0.24 −0.16 0.032
Hippocampus (left) −0.049 0.23 –0.085 0.27 0.046 0.53
Hippocampus (right) −0.018 0.6 −0.14 0.075 −0.015 0.84
Insula (left) 0.13 0.036 0.084 0.27 −0.037 0.61
Insula (right) 0.15 0.039 0.052 0.5 −0.073 0.32
Rostral ACC (left) 0.066 0.17 −0.12 0.11 −0.058 0.43
Rostral ACC (right) 0.088 0.34 −0.18 0.017 −0.018 0.8
vmPFC (left) 0.12 0.23 −0.2 0.0093 −0.12 0.093
vmPFC (right) 0.077 0.21 −0.21 0.0063 −0.076 0.3
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and observed significant associations in the right amygdala
and a non-significant trend for association with the left
vmPFC (Fig. 4a, b). Individual results for the original 96
probes are reported in Supplementary Table S10. Together,
the results suggest that DNA methylation changes in
response to alcohol exposure have the potential to mediate
altered brain activity patterns through alteration of HPA
axis activity and stress sensitivity.
Association of AUD DNA methylation module
eigenvector with hippocampal structure
In light of the observed AUD associations with epigen-
etic regulation of cortisol signaling and previous work
demonstrating associations of cortisol with limbic cortical
volume [49], we investigated available structural mea-
sures with AUD associated epigenetic variation. In
the discovery sample, the AUD associated coregulated
module eigenvector was significantly associated with
right, but not left hippocampal volume after adjusting for
age, sex, and race (right β= 546.55 ± 200.021, F= 7.103,
df= 5/177, p= 0.0069; left β= 395.528 ± 219.9, F=
3.97, df= 5/177, p= 0.074) (Fig. 4c).
Association of AUD and DNA methylation in
postmortem tissue
Both PRKCZ and GAS5 were consistently identified in
two independent brain tissue cohorts, suggesting these
may be among the most robust brain related findings
identified. Of the 96 target probes identified in the dis-
covery and first blood replication datasets, only 27 were
available for examination in the NICHD postmortem brain
dataset (due to differences in the array platforms EPIC
850K versus 450K). In FACS isolated glial tissue, alcohol
use status (N= 29 cases, N= 29 controls) was associated
with PRKCZ methylation (Supplementary Table S11). In
neuronal tissue, alcohol use status (N= 29 cases, N= 29
controls) was associated with methylation levels of
GAS5, GLTSCR1, and B2M (Supplementary Table S11).
Methylation data were available for 34 of the 96 target
probes in the Australian Brain Bank postmortem brain
dataset (N= 23 cases, N= 23 controls) (GSE49393).
DNA methylation of probes located within UBA3,
CABLES1, MYST3, GAS5, MYH10, TOLLIP, HNRNPA-1,
PRKCZ, and GLTSCR1 was significantly associated with
AUD status (Supplementary Table S11).
Expression analysis of GAS5 in human postmortem
brain
Given the consistent association of GAS5 methylation with
AUD phenotypes, we analyzed expression of GAS5 in 11
individuals with AUD and 13 controls using human post-
mortem brain tissues including amygdala and prefrontal
cortex. Results showed statistically significantly increased
GAS5 expression in the amygdala in AUD (p < 0.05)
(Fig. 5), indicating a potential effect of alcohol on GAS5
expression.
Discussion
This work represents the largest and most comprehensive
EWAS on AUD to date. The large number of significant
probes identified in our study may derive both from the
statistical power inherent in large cohorts as well as
widespread epigenetic changes induced by chronic alcohol
exposure. In our discovery cohort, we identified over 5000
DNA methylation associations with AUD after correction
for multiple testing. Importantly, while many of these
associations are likely biologically relevant, we sought
a means beyond statistical stratification to identify the
strongest findings from this set. Cross referencing
Fig. 4 Brain phenotypes as a function of AUD module variation.
a A scatterplot of amygdala BOLD activation (x axis) as a function of
AUD associated module eigenvector variation (y axis) in the fear
cohort. b A scatterplot of vmPFC BOLD activation (x axis) as a
function of AUD associated module eigenvector variation (y axis) in
the fear cohort. c A scatterplot of right hippocampal volume (x axis) as
a function of AUD associated module eigenvector variation (y axis) in
the discovery cohort.
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discovery findings with those derived from independent
replication sets represents a powerful tool to identify
robust findings with likely biological meaning. Using this
method, we identified 96 loci consistently associated with
both our initially discovered ~5000 FDR significant probes
and the 203 FDR significant probes in our first replication
set. The overlap between these cohorts was much higher
than expected by chance as was an enrichment of multiple
biological pathways exhibiting epigenetic change. We
further attempted to replicate our findings in a second
and third independent population-based cohort. Assess-
ment of the GS cohort revealed 70 of the 96 probes to be
significantly associated with alcohol use. The GTP data
was generated on an earlier technology, the HM450
microarray, and contained only 35 of the 96 loci above, of
which 15 loci were identified to be associated with
SCID based AUD diagnoses. Genes associated with these
probes included GAS5, MYST3, UBA3, HECW2, MYH10,
RASGRP1, PRKCZ, and FKBP5. Gene ontology (GO)
analysis demonstrated strong evidence for AUD associated
epigenetic alterations in genes associated with immune
response, glucocorticoid signaling and various inflamma-
tory cytokines (Supplementary Table S12). Notably, the
effects of alcohol exposure on inflammatory processes are
well documented. Alcohol exposure can activate both
acute and chronic inflammatory processes, both in brain
[50] and liver [51].
Given that methylomic variation across the genome is
not independent and likely coregulated by various sys-
tematic influences, we sought to further disentangle and
model the biological complexity of identified CpG sites in
our sample. We used WGCNA to generate a data driven
grouping of loci most likely to be coregulated in association
with AUD. One module consisting of 50 loci was associated
with AUD status and contained a number of loci relevant to
alcohol exposure (Result S1), including glucocorticoid
signaling and inflammation. Interestingly, our data are in
line and partially replicate a recent study of DNA
methylation in human postmortem brain, which identified
probes in the glucocorticoid receptor and FKBP5 in AUD
[22].
Based on these promising findings, both from a single
CpG standpoint (robust findings for GAS5 across all data-
sets) and the WGCNA analyses, we conducted several
follow up experiments to investigate biological function
with relevance to human stress responsiveness.
First, we established that the AUD WGCNA module was
associated with morning cortisol levels. Remarkably, of
those 50 loci interrogated, a network mediation analysis
suggested that a probe in GAS5 exhibited the highest evi-
dence for connectedness in association to cortisol regulation
by mediating the association with cortisol across a large
number of module genes. GAS5 interacts with the gluco-
corticoid receptor (GR) to inhibit its transcriptional function
[52] by folding into a soluble glucocorticoid response
element-like sequence on the GR to mimic GR binding
[53]. Furthermore GAS5 expression may also alter cortico-
trophin releasing hormone receptor 1 (CRHR1) expression
[54]. This finding is intriguing, given robust literature
supporting an involvement of the corticotropin releasing
factor and its receptor in AUD [55–60].
Second, we used neuroimaging paradigms to probe key
regions implicated in stress responsiveness in human, to
further explore biological mechanisms of identified CpG-
related networks. Main brain regions implicated in the
human stress response include the amygdala, frontal cortex,
and hippocampus, among others [61, 62]. Importantly, we
aimed to explore the neuronal and functional relevance of
peripherally identified epigenetic changes. As demonstrated
by our group previously, such peripherally identified epi-
genetic effects may have brain relevance when they derive
from a systemic factor such as circulating steroid hormones
[63] or alcohol [27]. We focused mainly on the frontal
cortex, hippocampus and amygdala. To probe the amygdala
specifically, we used a fear conditioning and extinction
paradigm in individuals with AUD and controls. Our data
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showed robust association of AUD-associated DNA
methylation with amygdala activation to the anticipation of
electric shocks in humans. These data suggest that the
AUD-associated coregulated module genes are associated
with BOLD signals in distinct brain regions, which in turn
may reflect brain-related phenotypes (Supplementary
Table S10, Result S1). Remarkably, AUD module epige-
netic variation was also associated with hippocampal
volume, suggesting a further link between peripheral DNA
methylation variation and brain phenotypes. Summarizing
our endophenotypes studies, we observed that GAS5 DNA
methylation was associated with alcohol use across all
studied cohorts both in the periphery and in the brain.
Furthermore, we studied GAS5 gene expression by con-
ducting postmortem studies of AUD patients and controls
and found higher GAS5 expression in the amygdala. This is
intriguing, given the fMRI finding in the amygdala, it
suggests a potential direct role of GAS5 in this brain region,
while further corroborating the functional relevance of our
results. The importance of GAS5 on phenotypic outcomes
may be attributed to its implicated role as a ‘hub gene’
regulating glucocorticoid signaling. GAS5 exhibited strong
module membership (hub status) and demonstrated evi-
dence for a high degree of network connectedness in
association with cortisol levels, suggesting it may play a
central role in the observed association between AUD co-
regulated module variation and cortisol status. It further
suggests that BOLD-associated epigenetic variation may be
a downstream consequence of or interact with dysregulated
glucocorticoid signaling. These results are consistent with
the known function of GAS5 and other module genes
exhibiting evidence for coregulation such as FKBP5 as both
are involved in modulating glucocorticoid signaling, and
broadly, inflammation. As such, previous evidence linking
FKBP5 to AUD may be in some way be related to GAS5
and should be investigated further. For example, FKBP5 is
transcribed by the GR and, once expressed, represents a
potent intracellular inhibitor of GR function [52]. FKBP5
gene expression has been suggested as an important med-
iator of the pathways to the development of drinking
behavior. Previous studies show that genetic variants within
FKBP5 that affect its expression mediate effects of both
poor parental relationships [64] and metacognitions about
alcohol on problematic drinking behavior [65]. These
findings hint at genetic effects that modulate FKBP5
expression, which may contribute to AUD. Similar to our
results, a recent study showed methylation changes in
FKBP5 in the prefrontal cortices of adults with alcohol use
problems [22]. Concurrently, animal studies demonstrate
that FKBP5 expression in mesocorticolimbic dopaminergic
neurons mediates the effects of early life stress on alcoholic
behavior [64]. While we observed epigenetic associations
with FKBP5 in three cohorts (discovery and replication
AUD, GTP), we could not detect such an effect in the GS
sample, possibly due to variation in the degree of trauma/
early life stress exposure. Moreover, epigenetic variation in
FKBP5 is particularly interesting in the context of fear
conditioning, as was tested in our study participants.
FKBP5 may confer risk to fear extinction deficits [66],
while, epigenetic regulation of FKBP5 has been proposed as
a mechanism to mediate glucocorticoid exposure enhanced
fear extinction in rodents [67].
Despite our promising findings, there are some limita-
tions that should be carefully considered. While we used
several cohorts to replicate methylomic variation associated
with AUD, it is important to keep in mind that other factors
besides alcohol might influence epigenetic signatures, such
as clinical heterogeneity and environmental factors includ-
ing life-experiences, trauma, diet, exercise patterns, and
underlying genetic architecture. In addition, the mechan-
isms by which alcohol leads to widespread epigenetic
reprogramming are not addressed by our study. One pos-
sibility is that epigenetic change is the downstream con-
sequence of the secondary effects of alcohol exposure such
as inflammatory changes or disrupted glucocorticoid sig-
naling. Alternatively, other loci may represent more direct
mediators of the effects of alcohol on phenotype or etiolo-
gical factors leading to the AUD phenotype. For example,
acute alcohol consumption can lead to brain expression
changes in PRKCZ (one of the replicating genes identified
in our study that was not a member of the AUD associated
coregulated module), suggesting it may be a consequence of
alcohol exposure. Alternatively, deletion of PRKCZ in mice
leads to increased consumption of alcohol [68] suggesting
that variation in PRKCZ precedes the AUD phenotype.
Similarly, methylation at GAS5 could reflect a mediating
effect of alcohol. Previous work has demonstrated that
GAS5 is bound by the catalytic EZH2 subdomain of poly-
comb group complex 2 (PRC2) [69]. Further, a recent report
highlighted a mechanism whereby alcohol exposure resul-
ted in histone 3 lysine 27 trimethylation marks (within the
amygdala) on a brain-derived neurotrophic factor associated
long non-coding RNA by EZH2 [70]. Although the degree
to which such a mechanism is generalizable for other non-
coding RNAs like GAS5 has yet to be determined, it is
possible that DNA methylation of GAS5 is affected by
interaction with PRC2 and which reflects a mediating effect
of alcohol via EZH2. As such, the translation from histone
modifications to DNA methylation through sequestration of
DNA methyltransferase activity at this specific locus will
need to be determined through future studies. Importantly,
understanding the cause vs. effect nature of the identified
associations is not possible in a cross-sectional design such
as the one applied in our study and calls for comprehensive
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longitudinal studies paired with preclinical animal work to
better understand etiological mechanisms in humans.
Despite this, consistent AUD associated findings across
multiple cohorts suggest the possibility of identifying a
combined ‘biosignature’ of AUD. A better understanding of
the association of epigenetic variation with not only the
diagnostic criteria itself, but also disease-associated endo-
phenotypes such as brain imaging alterations may even-
tually aid in the development of objective clinical tools to
assess for exposure to alcohol and the progression through
various phases of drinking behavior severity.
A strength of this study is the use of both diagnostic and
dimensional definitions of chronic alcohol use. Across
cohorts with various definitions, we continued to find the
same probes to be differentially methylated in response to
alcohol use, suggesting that the probes identified here are
particularly robust indicators of alcohol induced epigenetic
changes.
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